I spy Dr Noe and Frank Hudson at Agensys
This article was originally published in Scrip
Agensys, a subsidiary of Astellas which is developing a pipeline of therapeutic fully human monoclonal antibodies to treat cancers, has appointed Frank Hudson vice-president of finance, and Dr Wolfgang Noe vice-president of process sciences and manufacturing. Mr Hudson joins Agensys from Mannkind Corporation where he had served as vice-president of finance since 2007. Dr Noe most recently served as vice-president of strategic development and technical alliances at Biogen Idec.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.